Genix Pharmaceuticals Corporation (GENPF)

Market Cap	1.28M
Revenue (ttm)	2.75K
Net Income (ttm)	-83.87K
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	11,817
Open	0.0470
Previous Close	0.0260
Day's Range	0.0400 - 0.0470
52-Week Range	0.0260 - 0.0470
Beta	0.45
RSI	46.49
Earnings Date	Mar 31, 2025

About Genix Pharmaceuticals

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. It also markets and sells nutraceuticals and pharmaceutical products, su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: GENPF

Financial Performance

In 2024, Genix Pharmaceuticals's revenue was 4,051, a decrease of -67.19% compared to the previous year's 12,347. Losses were -73,196, -98.33% less than in 2023.

Financial numbers in CAD